Autopsy report · NCT04677426

129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study

“Sponsor withdrew Funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

University of Kansas Medical Center

Sponsor type

University, hospital or other

Conditions

Idiopathic Pulmonary Fibrosis; Hypersensitivity Pneumonitis

Interventions

Hyperpolarized Xe129

Participants

0

Trials that died the same way

• Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
  “Funding withdrawn by sponsor” (96% match in meaning)
• Lucentis for New Onset Neovascular Glaucoma
  “Company withdrew funding/sponsorship” (91% match in meaning)
• Study of Regional Cerebral Oxygenation and Brain Blood Volume Changes During Carotid Endarterectomy Using the NeurOS System
  “sponsor withdrew” (90% match in meaning)
• Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study
  “sponsor withdrew support” (89% match in meaning)
• ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children
  “Withdrawal of funding from primary sponsor” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.